N/A
N=24
Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries
Pain, Acute · Pain, Chronic
Bottom Line
View on ClinicalTrials.gov: NCT03187132 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: PROMIS - Physical Function Short Form 8b — 34.5; 38.6 units on a scale — p=.111
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Digital Pain Reduction Kit (Device); Active Control (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cedars-Sinai Medical Center
- Primary completion
- May 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PROMIS - Physical Function Short Form 8b |
34.5; 38.6 | .111 |
| SECONDARY PROMIS - Pain Interference Short Form 8a |
64.8; 63.2 | .612 |
| SECONDARY Work Productivity and Activity Impairment Questionnaire : Lower Back Pain (WPAI:SHP v2.0) |
26.9; 26.4; 7.3; 7.1; 7.1; 7.0 | .87 |
| SECONDARY Patient Satisfaction Questionnaire (PSQ) 18 |
3.25; 3.49; 3.55; 3.84; 3.2; 3.52 | .467 |
| SECONDARY Binary, Self-reported Opioid Use |
11; 15 | .852 |
Summary
This study will test the effectiveness of an evidence-based, multi-modal, "digital pain-reduction kit" as a non-pharmacological supplement to managing patients with pain due to musculoskeletal injuries. Outpatients will be randomized to receive either the pain reduction kit or active control. The kit will contain a virtual reality (VR) headset, therapeutic VR visualization software, and a low-cost wearable transcutaneous electrical nerve stimulation (TENS) unit. Clinical staff will monitor progress and provide scheduled coaching and outreach to patients in the intervention group. The control group will receive the low-cost wearable transcutaneous electrical nerve stimulation (TENS) unit alone; they will not receive VR or remote coaching. Study devices will be delivered to the patient's home with instructions for use; patients will receive remote clinical and technical support. Patients will be followed for 60 days and monitored for functional status, pain levels, use of pain medications (including opioids), satisfaction with care, and time to returning to work.
Eligibility Criteria
Inclusion Criteria
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, age 18 or older
- Seeking care for a musculoskeletal injury
- Experiencing pain greater than 3 out of 10 on a visual analog scale
- English or Spanish speaking
- Owns a compatible Android or iOS smartphone device (excluding tablets)
Exclusion Criteria
- Unable to understand the goals of the study due to cognitive difficulty
- Use of a cardiac pacemaker, implanted defibrillator, or other implanted metallic or electronic device or high-frequency surgical equipment. (contraindication for TENS units)
- Pregnant (contraindication for TENS unit)
- Current diagnosis of epilepsy, dementia, or other neurological disease that may prevent use of VR hardware or software
- Hypersensitivity to flashing light or motion
- Injury to the eyes, face, neck, or arms that prevents comfortable use of VR hardware or software, or safe use of other study hardware (e.g., open sores, wounds, or skin rash on face)
Data sourced from ClinicalTrials.gov (NCT03187132). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.